{"nctId":"NCT02553798","briefTitle":"Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis","startDateStruct":{"date":"2015-08"},"conditions":["Hyperhidrosis"],"count":564,"armGroups":[{"label":"Glycopyrronium","type":"EXPERIMENTAL","interventionNames":["Drug: Glycopyrronium Topical Wipes"]}],"interventions":[{"name":"Glycopyrronium Topical Wipes","otherNames":["DRM04"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completed Day 28 of either the DRM04-HH04 or DRM04-HH05 study with at least 80% treatment compliance\n* Male or females\n\nExclusion Criteria:\n\n* Subject has a clinically significant abnormality on physical exam, vital signs or ECG at the Week 4 visit of DRM04-HH04 or DRM04-HH05 study that would make further treatment with glycopyrronium contraindicated\n* Male with a history of urinary retention requiring catheterization due to prostatic hypertrophy or severe obstructive symptoms of prostatic hypertrophy\n* Any other condition which, in the judgement of the Investigator, would put the subject at unacceptable risk for participation in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"9 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Long-term Safety Assessed Through Adverse Events and Local Skin Reactions","description":"The Total Participants at risk are based on the Safety population, defined as, Participants who were randomized and received at least one confirmed dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"148","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"153","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean Absolute Change From Baseline in Gravimetrically-measured Sweat Production at Week 4","description":"Subjects are acclimated to the environment for 30 minutes. Dry gauze is weighed. The dry gauze is then applied to the subject's axilla with the arm down by the subject's side or on their lap during the 5-minute period of sweat production. The gauze with the sweat is then weighed. The difference between the Weight of the gauze with sweat and the dry gauze is the gravimetric sweat measurement in mg/5min.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-95.68","spread":"140.806"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Grade Improvement in Hyperhidrosis Disease Severity Scale (HDSS)","description":"Hyperhidrosis Disease Severity Scale (HDSS) is a disease specific diagnostic tool that provides a qualitative measure of the severity of the subjects' condition based on how it affects daily activities.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"204","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"135","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 44/ET","description":"The Dermatology Life Quality Index DLQI is a ten question questionnaire, used to measure the impact of skin disease on the quality of life of an affected person. The scoring of each question is as follows: Very much (3), A lot (2), A little (1), Not at all (0), Not relevant (0). Is calculated by summing the score of each question resulting in a max of 30 and a min of 0. Higher the score the more Quality of life is impaired.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.7","spread":"6.24"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":550},"commonTop":["Dry Mouth","Vision blurred","Application Site Pain","Nasopharyngitis","Mydriasis"]}}}